comparemela.com

Latest Breaking News On - Poseida therapeutics inc - Page 1 : comparemela.com

Critical Contrast: Biogen (NASDAQ:BIIB) and Poseida Therapeutics (NASDAQ:PSTX)

Biogen (NASDAQ:BIIB – Get Free Report) and Poseida Therapeutics (NASDAQ:PSTX – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations. Profitability This table compares Biogen and Poseida Therapeutics’ net […]

Germany
California
United-states
Massachusetts
Cambridge
Cambridgeshire
United-kingdom
San-diego
Alkermes-pharma-ireland
Sangamo-therapeutics-inc
Biogen-inc

Poseida Therapeutics Announces Virtual 2024 Annual Meeting Of Stockholders

SAN DIEGO, June 3, 2024 /PRNewswire/ Poseida Therapeutics, Inc. (Nasdaq: PSTX ), a clinical-stage allogeneic cell therapy and genetic medi

Poseida-therapeutics-inc
Linkedin
Nasdaq
Annual-meeting
Poseida-therapeutics
Specific-gene-editing-system
Booster-molecule

Equities Analysts Offer Predictions for Poseida Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:PSTX)

Poseida Therapeutics, Inc. (NASDAQ:PSTX – Free Report) – Investment analysts at HC Wainwright upped their Q2 2024 EPS estimates for Poseida Therapeutics in a research report issued to clients and investors on Wednesday, May 22nd. HC Wainwright analyst A. He now anticipates that the company will earn ($0.43) per share for the quarter, up from […]

Tower-research-capital
Poseida-therapeutics-inc
Nasdaq
Poseida-therapeutics-company-profile
Dynamic-technology-lab-private-ltd
Keystone-financial-group
Allspring-global-investments-holdings
Poseida-therapeutics
Free-report
Poseida-therapeutic
Get-free-report

Poseida Therapeutics' (PSTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX – Free Report) in a research note published on Wednesday, Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock. HC Wainwright also issued estimates for Poseida Therapeutics’ Q2 2024 earnings at ($0.43) EPS, Q3 2024 earnings at ($0.46) EPS, […]

Ohio
United-states
Mirae-asset-global-investments-co
Poseida-therapeutics-inc
Silverarc-capital-management
Nasdaq
Barclays-plc
Poseida-therapeutics
Free-report
Get-free-report
Capital-management

Poseida Therapeutics' (PSTX) Buy Rating Reaffirmed at HC Wainwright

Poseida Therapeutics (NASDAQ:PSTX – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $20.00 price target on the stock. Poseida Therapeutics Price Performance Poseida Therapeutics stock opened at $2.97 on Wednesday. Poseida Therapeutics has a one […]

Poseida-therapeutics-inc
Tower-research-capital
Allspring-global-investments-holdings
Keystone-financial-group
Dynamic-technology-lab-private-ltd
Poseida-therapeutics
Get-free-report
Capital-management
Technology-lab-private-ltd
Research-capital
Global-investments-holdings

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.